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1 Abstract 
Background: Heightened threat sensitivity is a transdiagnostic feature in several psychiatric 
disorders. The neuropeptide oxytocin has been shown to reduce fear related behaviours and 
facilitated fear extinction in animals. These findings have led to increasing interest to explore the 
effects of intranasal oxytocin on threat processing in humans. 
 
Methods: The review included 26 studies (N = 1173), nine of which included clinical populations (N = 
234). The clinical groups included were people with borderline personality disorder (BPD), anorexia 
nervosa, bulimia nervosa, depression, anxiety, and alcohol dependence disorder. We examined the 
effects of a single dose of intranasal oxytocin on startle response, attentional responses, and 
behavioural responses to threat.  
 
Results: A single dose of intranasal oxytocin significantly increased the physiological startle response 
to threat in healthy people with a small effect size. However, oxytocin did not have significant effects 
on attentional bias towards social or disorder-specific threat, fixation towards threatening stimuli 
among healthy or clinical populations, or on threat related behavioural approach or avoidance 
responses.  
 
Limitations: No studies investigated the effects of oxytocin on the startle response to threat among 
clinical populations. Additionally, only one of the reviewed studies had sufficient power to detect at 
least a moderate effect of oxytocin according to our criterion. 
 
Discussion: The synthesis of literature suggest that oxytocin may influence the salience of 
threatening stimuli among healthy individuals, increasing the startle response to threat. It would be 
of interest to investigate the effects of oxytocin on the startle response to threat among clinical 
populations.   
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2 Introduction 
Threat processing is vital for the survival of an organism or species (Öhman, 2005; Öhman, 2007). 
Potential threats are rapidly recognised and activate a number of subcortical structures including the 
amygdala and the hypothalamic-pituitary-adrenal (HPA) axis, which initiate protective fear responses 
(Öhman 2005). Physiological responses, such as increased skin conductance, behavioural approach 
and avoidance responses, such as fight or flight responses, and attentional responses, such as active 
attending to the source of fear also occur (Misslin 2003). However, hypersensitivity of this system 
and maladaptive fear learning can have negative consequences (Ozawa and Johansen, 2014). Such 
maladaptive processes are believed to contribute to the development and maintenance of number 
of psychiatric disorders, such as eating disorders (ED), anxiety disorders, obsessive-compulsive 
disorder (OCD), and post-traumatic stress disorder (PTSD) (Britton et al., 2011; Ozawa and Johansen, 
2014; Strober et al., 2007). 
 
Behavioural studies have demonstrated that people with PTSD, OCD, and ED show anomalies in 
physiological response to threat. For example, there is an exaggerated physiological startle response 
to anticipation and viewing of disorder-specific, potentially threatening stimuli, such as images of 
trauma, contamination, or food (Altman et al., 2013; Mauler et al., 2006; Pitman et al., 2012; Simon 
et al., 2013). Additionally, a number of reviews have reported atypical attentional bias towards 
disorder specific stimuli (Bar-Haim et al., 2007; Brooks et al., 2011; Cisler and Koster, 2010). 
Furthermore, disorder specific stimuli have been found to elicit negative facial expressions and 
subjective feelings of fear and disgust (Broderick et al., 2013; Soussignan et al., 2011; Uher et al., 
2004). Taken together these findings suggest that treatments targeting this hypersensitivity and 
maladaptive fear learning may be of benefit. 
 
The neuropeptide, oxytocin, has been found to play an important regulatory role in human and 
animal studies (Neumann and Slattery, 2016; Onaka et al., 2012; Zheng et al., 2010). Animal studies 
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have demonstrated that oxytocin plays an important role in lowering the physiological stress and 
anxiety response by activating a negative feedback loop (Onaka et al., 2012; Zheng et al., 2010). 
Elevated oxytocin secretion from the paraventricular nucleus of the hypothalamus following a 
stressful event is believed to lead to increased availability of gamma-aminobutyric acid (GABA), 
which in turn is believed to inhibit the HPA axis and amygdala activation (Onaka et al., 2012; Zheng 
et al., 2010). Indeed, a recent study found that marmoset monkeys treated with an oxytocin 
receptor antagonist had elevated glucocorticoid levels in response to the stressor and showed a 
greater tendency to engage in maladaptive fear-related behaviour such as isolation (Cavanaugh et 
al., 2016). These findings have sparked increasing interest in exploring the role of oxytocin in threat 
processing, particularly in fear responses and extinction learning.  
 
Preclinical studies demonstrated that exogenous intravenous and intranasal oxytocin can influence 
fear related responses in rodents and monkeys respectively, reducing hiding behaviour during an 
open field test and attentional bias towards threatening facial expressions (Parr et al., 2013; 
Rotzinger et al., 2010). Additionally, a recent systematic review explored the role of the oxytocin 
system in fear extinction in rodents (Neumann and Slattery, 2016). The findings revealed that 
oxytocin reduced fear related behaviours and facilitated fear extinction in rodents, particularly when 
the exogenous oxytocin or oxytocin agonists were administered to the infralimbic cortex (Neumann 
and Slattery, 2016). The infralimbic cortex has inhibitory projections to a number of subcortical 
regions in the rodent brain including the amygdala and activation of this region has been 
documented to be associated with fear extinction in rodents and humans (Quirk and Beer, 2006). 
These findings suggest that oxytocin may reduce fear and facilitate extinction possibly by reducing 
stress and anxiety around the source of potential threat. Thus, these findings have led to increasing 
interest to investigate the role oxytocin plays in threat processing and fear extinction in humans as 
well as its therapeutic potential in disorders characterised by elevated threat sensitivity and 
resistance to natural extinction. 
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 A few studies have begun to explore the effects of intranasal oxytocin on threat processing and the 
physiological stress and anxiety response in humans. For example a recent meta-analysis found that 
a single dose of intranasal oxytocin lowered cortisol in clinical populations characterised by 
dysregulation of the HPA axis, but did not significantly influence the cortisol response to stressful 
stimuli in healthy individuals (Cardoso et al., 2014). Since many psychiatric disorders, including ED, 
PTSD, and anxiety disorders, are characterised by dysregulation of the HPA axis (Connan et al., 2007; 
Ehlert et al., 2001; Lo Sauro et al., 2008), there has been increasing interest in further exploration of 
the potential anti-stress and anxiolytic effects of intranasal oxytocin in psychiatric disorders 
characterised by elevated threat sensitivity. To our knowledge, no systematic reviews have thus far 
investigated the effects of single dose of intranasal oxytocin on different aspects of threat processing 
in healthy and clinical populations more broadly.  
 
The aim of the current systematic review and meta-analyses was to build on previous literature and 
synthesise studies examining the effects of a single dose of intranasal oxytocin on threat processing 
among in humans. The objective was to investigate the effects of oxytocin on the physiological 
startle response, behavioural approach and avoidance responses, and attentional responses, 
including attentional bias and fixation, towards generally threatening stimuli as well as towards 
disorder related threatening stimuli among clinical populations. Based on findings outlined above, 
we hypothesised that a single dose of intranasal oxytocin would reduce these anomalous threat 
responses in clinical populations characterised by elevated threat sensitivity. 
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3 Methodology 
3.1 Literature search 
In accordance with the PRISMA guidelines (Moher, Liberati, Tetzlaff, & Altman, 2009), electronic 
databases, including OVID (PsycINFO, PsycARTICLES, Medline, ARGIS), Web of Knowledge core 
collection, and Pubmed, were searched April 2017. The search terms included oxytocin AND (threat 
OR fear OR anxiety OR avoidance OR attention OR bias OR startle OR approach OR fixation OR gaze). 
Furthermore, bibliographies of included studies were inspected to look for further studies not 
yielded by the initial search. 
 
3.2 Inclusion criteria 
In order to be included in the systematic reviews and meta-analyses studies were required to meet 
the following inclusion criteria: 1) investigate physiological response, behavioural approach and 
avoidance response, attention, or fixation towards threatening or feared stimuli; 2) investigate the 
effects of a single dose of intranasal oxytocin on these measures; 3) compare the effects of 
intranasal oxytocin against intranasal placebo; 4) include healthy adult participants and/or adult 
clinical populations; 5) random allocation of participants to receive intranasal oxytocin or placebo in 
studies using between subjects design; 6) randomisation of treatment order in studies using within 
subjects design; 7) be published in English in a peer reviewed journal. In order to reduce 
heterogeneity, long trials in which participants received more than one dose of oxytocin or in which 
effects of oxytocin were investigated the following day or later were not included.  
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3.3 Study selection 
The search flow diagram is presented in Figure 1. The literature search and initial screening based on 
title and abstract was conducted by the first author. The full text articles identified in the initial 
search and screening were examined for eligibility by two authors in conjunction (J.L. and K.W.N.). 
Studies were then included in the systematic review and meta-analyses if both authors agreed they 
met the inclusion criteria. If there was any uncertainty regarding eligibility of a paper it was referred 
to the rest of team for further discussion.  
 
Figure 1. Literature search flow diagram 
-----------------------------------------------------------FIGURE 1-------------------------------------------------------------- 
 
3.4 Data collection and synthesis 
We conducted three separate meta-analyses investigating the effects of a single dose of intranasal 
oxytocin on the physiological response, behavioural approach and avoidance response, attention, 
and fixation towards threatening stimuli. To conduct these meta-analyses information regarding 
means, standard deviations, and sample size were extracted from the included articles. Where 
standard errors of the mean (SE) were reported instead of standard deviations, these were 
converted with the following formula:         √ . Fourteen studies did report the data in the 
article or in supplementary materials, or reported the data in figures only. In order to acquire the 
required data, the corresponding authors of these papers were contacted by one of the authors. The 
relevant data was obtained from the following studies via personal communication: Acheson et al. 
(2013); Bertsch et al. (2013); Eckstein et al. (2015); Eckstein et al. (2016); Hubble et al. (2017); Kim et 
al. In prep; Leknes et al. (2013); Preckel et al. (2014); Striepens et al. (2012). Despite contacting 
corresponding authors, we were unable to gain access to the relevant data from eight studies. 
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In addition to healthy individuals, clinical populations included in the study consisted of people with 
anorexia nervosa (AN), bulimia nervosa (BN), depression, and BPD. Information regarding 
participants’ age, dose of oxytocin (in international units), the type of task used, the stimulus 
presentation time in milliseconds (ms), the study design (between subjects, within subjects), and the 
proportion of female participants in the study, was also extracted from the articles for the purposes 
of meta-regression.  
 
Where appropriate, information regarding psychopathology was extracted from the studies. This 
information was extracted from the three studies that investigated the effects of a single dose of 
intranasal oxytocin on attentional bias to disorder-specific stimuli. This information consisted of self-
reported anxiety measured with the Depression, Anxiety and Stress Scale (DASS) and Spielberger 
State and the Trait Anxiety Inventory (STAI), self-reported depression measured with the DASS and 
Beck Depression Inventory (BDI), and self-reported ED psychopathology measured with the Eating 
Disorder Examination Questionnaire. Self-reported anxiety and depression scores were converted to 
standardised z-scores prior to being included in the meta-regression.  
 
Finally, we also conducted a systematic review of studies investigating the effects of a single dose of 
oxytocin on behavioural approach and avoidance. We were not able to conduct a meta-analysis due 
to a small number of studies and differences in outcome measures used.  
 
3.5 Tasks used to examine threat processing 
3.5.1 Startle response  
Seven studies investigated the effects of a single dose of intranasal oxytocin on the physiological 
response to general threat and learned threat (Table 1). Four studies investigated the effects of 
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intranasal oxytocin on the physiological response to generally threatening stimuli, including angry 
faces, images of threatening scenes, and predictable and unpredictable electric shocks (Grillon et al., 
2013; Leknes et al., 2013; Prehn et al., 2013; Striepens et al., 2012). Three studies investigated the 
effects of oxytocin on startle response to learned threat cues after conditioning and on learned 
threat following extinction (Acheson et al., 2013; Eckstein et al., 2015; Eckstein et al., 2016). The 
outcomes measures included eye blink magnitude, skin conductance response, pupil dilation, and 
facial electromyography (EMG). All studies included only healthy individuals. One study reported 
data separately for male and female participants (Grillon et al., 2013).  
 
3.5.2 Approach and avoidance responses 
Five studies investigated the effects of a single dose of intranasal oxytocin on approach and 
avoidance responses to threatening images including angry faces and general negative stimuli (Table 
1). In this experimental paradigm participants are presented with threatening and neutral stimuli 
one at a time and asked to respond either by pulling or pushing a lever as quickly as possible. 
Pushing the lever shrinks the stimulus on the screen indicating avoidance of the stimulus, whereas 
pulling the lever zooms in on the stimulus on the screen indicating approach towards the stimulus. 
One study reported approach reaction times (Preckel et al., 2014) and another study reported 
reaction times for both approach and avoidance responses (Radke et al., 2017). Two other studies 
reported approach-avoidance bias scores (Mitchell et al., 2016; Radke et al., 2013). Positive bias 
scores indicated approach and negative bias scores indicated avoidance. Finally, one study did not 
report the relevant data but provided test statistics (Theodoridou et al., 2013). Four of the studies 
only included healthy individuals, one included people with alcohol dependence disorder, and one 
explored the effects of oxytocin in low and highly anxious people. Effect sizes and confidence 
intervals are reported for the four studies that provided the relevant data. 
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3.5.3 Attentional responses 
Two methods were used to investigate the effects of a single dose of intranasal oxytocin on 
attentional responses to threat: attentional bias towards threatening images relative to neutral 
images and fixation towards regions of interest within threatening images (Table 1). Seven studies 
investigated the effects of a single dose of intranasal oxytocin on attentional bias towards social 
threat, namely images of angry and disgusted faces. Six of the studies examined attentional bias 
using the dot-probe paradigm and one used a spatial cueing task. In these tasks participants are 
initially presented with a fixation cross followed by the presentation of a threatening stimulus either 
alone on one side of a computer screen or in combination with a neutral stimulus on opposite sides 
of the screen. After the threatening stimulus has disappeared, a target is presented either in the 
same place where the threatening stimulus was or on the opposite side of the screen. Participants 
are then asked to identify the target by pressing the appropriate key on a keyboard. In the dot-probe 
tasks attentional bias scores were calculated from the response times, subtracting response times in 
trials, where the probe replaced a neutral stimulus from response times in trials, where the probe 
replaced the threatening stimulus. Positive scores indicate increased attention towards the 
threatening stimuli while negative scores indicate reduced attention towards the threatening 
stimuli.  
 
In the spatial cueing task attentional bias and avoidance were investigated separately by examining 
reaction times in congruent trials, in which the target was presented in the same side of the screen 
as the threatening image, and incongruent trials, in which the target was presented on the other 
side of the screen relative to the threatening image (Ellenbogen et al., 2012). The final attentional 
bias scores are calculated by subtracting response time in the congruent neutral trials from response 
times in the congruent threatening trials. The attentional avoidance scores are scores are calculated 
by subtracting response time in the incongruent neutral trials from response times in the 
incongruent threatening trials. Thus, as above and despite different methods, positive scores 
11 
 
indicate increased attention towards the threatening stimuli and negative scores indicate reduced 
attention towards the threatening stimuli in both tasks. Further, two of the studies varied the cue 
presentation duration or used masked cue presentation (Brune et al., 2013; Domes et al., 2016; 
Ellenbogen et al., 2012). 
 
Three studies investigated attentional bias towards disorder-specific threatening stimuli in ED, 
namely AN and BN, using the dot-probe paradigm (Table 1). These studies used food, body shape, 
and body weight related images as threatening stimuli. As above, positive attentional bias scores 
indicated greater attention towards the disorder-specific threatening images, and negative scores 
indicated attention away from the stimuli. One of the studies varied the cue presentation duration 
(Kim et al., In prep.), and another study investigated attentional bias with varied inter-trial interval 
(500ms or 1250ms) before and after a smoothie challenge (Leppanen et al., 2017).  
 
Five studies investigated the effects of a single dose of intranasal oxytocin on attention towards 
regions of interest (ROIs) in threatening images using eye tracking (Table 1). Three of the studies 
defined the ROIs as the eye and mouth region of angry and disgusted faces (Bertsch et al., 2013; 
Domes et al., 2013; Hubble et al., 2017; Lischke et al., 2012a). One study investigated fixation 
towards predefined regions of interest in threatening scenes taken from the international picture 
affective system (Lischke et al., 2012b). The ROIs were predefined based on pilot data. The outcome 
measure was preferential fixation towards the ROIs relative to the rest of the face or the background 
of the image.  
 
3.6 Statistical analysis 
Statistical analyses were conducted with the Metafor package in R (R Core Team, 2015; Viechtbauer, 
2010). For studies using between subjects design, standardised, unbiased effect sizes were 
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estimated by calculating Hedges’ g (Hedges, 1981) and 95% confidence intervals. For studies using 
within subjects design standardised mean change with change score standardisation (SMCC) along 
with 95% confidence intervals was calculated. Where correlation between the two conditions was 
not reported to calculate the SMCC effect size estimate, the correlation was estimated using the 
following formula: 
                   
         
 (Morris and DeShon, 2002). The Hedges’ g and SMCC effect 
size estimates are both on the same scale and were interpreted as small (≥0.20), medium (≥0.50), 
and large (≥0.80). Positive effect sizes indicated oxytocin-induced increase in startle response, 
approach, and attention towards threatening stimuli. Negative effect sizes indicated oxytocin-
induced reduction in startle response, approach, and attention towards threatening stimuli. 
 
Because a number of studies used a variety of paradigms to investigate different aspects of threat 
processing, the same participants were included in a meta-analysis more than once. To account for 
confounding effects arising from this, we conducted multivariate meta-analyses with an auto-
regressive structure. Between-study heterogeneity was examined with the Cochran’s Q index. 
Significant heterogeneity between studies was further investigated with meta-regressions to 
examine the moderating effects of the following variables: age, the study design, the dose 
administered (in IU), the type of task used, diagnosis, the type of stimuli used, and the proportion of 
female participants in the sample. Significance level was set at p <  0.05.  
 
Presence of outliers was investigated by calculating standardised residuals of each study included in 
the meta-analyses. If the Z scores of the standardised residuals exceeded ±1.96, the study was 
deemed an influential outlier and was thus removed from the analyses (Viechtbauer and Cheung, 
2010).  
 
Publication bias based on funnel plot asymmetry was investigated with Begg’s rank correlation test 
(Begg and Mazumdar, 1994). Additionally, where significant effects were present their robustness 
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was assessed with the Rosenthal’s fail-safe N analysis (Rosenthal, 1979). The analysis provides a fail-
safe number of studies with non-significant results that would need to be included for the effects to 
be reduced to null. The effect is considered robust if the fail-safe N exceeds the Rosenthal criterion, 
5k+10, where k is the number of studies included in the meta-analysis (Rosenthal, 1991).  
 
Finally, we explored whether the included studies had large enough sample sizes to have adequate 
power to detect an effect of oxytocin on threat processing. According to the power analysis 
conducted with G*Power (Faul et al., 2007), between subjects studies should have at least 64 
participants in each group and within subjects studies should have at least 34 participants, to have 
80% power to detect a moderate effect.  
4 Results 
4.1 Study characteristics 
Characteristics of the 26 included studies are presented in Table 1. The effect size (ES) column shows 
the standardised effect size estimate along with 95% confidence intervals for each study. The power 
column show whether the study had a sufficiently large sample size to have 80% power to detect at 
least a moderate (ES ≥ 0.5) effect of oxytocin. Only one study using within subjects design met the 
sample size requirement of sufficient power.  Six other studies using within subjects design came 
close to having sufficient power (sample size ≥ 30). 
 
4.2 Effects of oxytocin on startle response to threat 
The studies investigating the effects of a single dose of intranasal oxytocin on physiological startle 
response to general threat and learned threat are presented in Figure 2. Overall, the meta-analysis 
revealed that intranasal oxytocin significantly increased startle response to threat with a small effect 
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size (ES = 0.32, 95% CI [0.13, 0.52], Z = 3.27, p = 0.001). We further explored the effects of oxytocin 
on startle response to general threat and learned threat following conditioning. Intranasal oxytocin 
significantly increased startle response to general threat with a small effect size (ES = 0.30, 95% CI 
[0.07, 0.53], Z = 2.55, p = 0.011). Oxytocin-induced increase in startle response following 
conditioning also approached significance with a small effect size (ES = 0.41, 95% CI [-0.01, 0.82], Z = 
1.90, p = 0.058).  
 
There was no significant between-study heterogeneity (Q = 11.32, p = 0.297, I2 = 29.00), and thus, no 
meta-regressions were conducted. Begg’s rank correlation test based on the funnel plots did not 
indicate there was evidence of significant publication bias (τ = 0.24, p = 0.359, Supplementary Figure 
1). The Rosenthal’s fail-safe N analysis revealed that 55 studies with non-significant results would 
need to be added to the present meta-analysis to reduce the observed effect to null. This exceeds 
the Rosenthal criterion (55 > (5x7+10) = 45) suggesting that the effect observed was robust. 
 
Figure 2. Forest plot of studies investigating the effects of intranasal oxytocin on the startle response 
to threat 
----------------------------------------------------------FIGURE 2--------------------------------------------------------------- 
Grillon et al. 2013(a) = female participants, Grillon et al. 2013(b) = male participants, Angry faces (f) = 
angry female faces, Angry faces (m) = angry male faces, EMG = electromyography. 
 
4.3 Effects of oxytocin on attentional responses towards threat 
4.3.1 Attentional bias towards social threat 
The studies investigating the effects of a single dose of intranasal oxytocin on attentional bias 
towards social threat are presented in Figure 3. Overall, a single dose of intranasal oxytocin did not 
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significantly influence attentional bias towards social threat (ES = -0.10, 95% CI [-0.50, 0.29], Z = -
0.51, p = 0.612). We then further explored the effects within the healthy and clinical populations. 
Among the healthy individuals, oxytocin did not significantly impact attentional bias towards social 
threat (ES = -0.42, 95% CI [-1.07, 0.23], Z = -1.26, p = 0.208). There was also no significant effects of 
oxytocin among the mixed clinical group (ES = 0.13, 95% CI [-0.35, 0.61], Z = 0.54 p = 0.593). 
 
The overall meta-analysis revealed significant between-study heterogeneity (Q = 73.53, p < 0.001), 
which was explored further with meta-regressions. Together the stimuli used, the stimulus 
presentation time, and the diagnostic group significantly moderated some of the between-study 
heterogeneity (QM = 43.41, p < 0.0001), still leaving significant residual heterogeneity (QR = 24.60, p 
= 0.004). This suggests that the effects of oxytocin on attentional bias were the strongest among 
highly anxious people and people with BPD when the angry faces were presented for 500ms or less 
time. However, only one study included people with BPD and only one study included highly anxious 
people and, thus, these findings should be interpreted with caution. The proportion of female 
participants in the study (QM = 0.03, p = 0.859), the study design (QM = 0.11, p = 0.744), age (QM = 
0.295, p = 0.589), the task used (QM = 0.29, p = 0.963), and the dose administered (QM = 0.01, p = 
0.929) did not significantly moderate the between study heterogeneity. 
 
The Begg’s rank correlation test based on the funnel plot asymmetry did not reveal evidence of 
significant publication bias (τ = 0.09, p = 0.565; Supplementary figure 2).  
 
Figure 3. Forest plot of studies investigating the effects of intranasal oxytocin on the attentional bias 
towards social threat 
----------------------------------------------------------FIGURE 3--------------------------------------------------------------- 
Ellenbogen et al. 2012 (a) = congruent trials, Ellenbogen et al. 2012 (b) = incongruent trials, AN = 
anorexia nervosa; BN = bulimia nervosa; BPD = borderline personality disorder, ms = milliseconds.  
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4.3.2 Attentional bias towards disorder-specific threat 
The studies investigating the effects of a single dose of intranasal oxytocin on attentional bias 
towards disorder-specific threatening stimuli are presented in Figure 3. Only studies including people 
with ED, namely AN and BN, had investigated these effects. The disorder-specific threatening stimuli 
consisted of negative body shape related, body weight related, and food related images.  
 
The meta-analysis showed that overall a single dose of intranasal oxytocin did not significantly 
influence attentional bias towards disorder-specific stimuli in eating disorders (ES = -0.05, 95% CI [-
0.28, 0.18], Z = -0.43, p = 0.670). We further explored the effect of a single dose of oxytocin 
separately on the different types of disorder specific stimuli used. Intranasal oxytocin did not 
significantly influence attentional bias towards negative body shape related stimuli (ES = -0.07, 95% 
CI [-0.66, 0.52], Z = -0.23, p = 0.818), body weight related stimuli (g = 0.09, 95% CI [-0.12, 0.30], Z = 
0.86, p = 0.388), or food related stimuli (ES = -0.10, 95% CI [-0.36, 0.15], Z = -0.79, p = 0.429).  
 
There was significant between-study heterogeneity (Q = 24.52, p = 0.017), which was explored 
further with meta-regressions. Diagnostic group significantly explained the between-study 
heterogeneity (QM = 6.37, p = 0.012), still leaving some unaccounted heterogeneity that approached 
significance (QR = 18.15, p = 0.078). This suggests that people with BN showed greater oxytocin 
induced increase in attentional bias towards disorder-specific stimuli (ES = 0.15, 95% CI [-0.03, 0.33], 
Z = 1.66, p = 0.096), whereas people with AN showed greater oxytocin-induced increase in 
attentional avoidance of disorder-specific stimuli (ES = -0.16, 95% CI [-0.33, 0.03], Z = -1.92, p = 
0.055). However, neither of these effects reached significance and only one study investigated the 
effects of oxytocin in people with BN. Therefore, these findings should be interpreted with caution.  
Self-reported anxiety (QM = 0.20, p = 0.655), self-reported depression (QM = 1.41, p = 0.235), self-
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reported eating disorder symptomatology (QM = 0.04, p = 0.846), the stimuli used (QM = 1.56, p = 
0.458), age (QM = 0.01, p = 0.937), and variations in the task used (QM = 0.08, p = 0.995) did not 
significantly moderate the between study heterogeneity. The proportion of female participants in 
the study, the dose administered, and the study design were not entered as predictors in the meta-
regression as all included studies recruited only female participants, used the same within subjects 
design, and administered the same dose oxytocin. 
 
The Begg’s rank correlation test based on the funnel plot asymmetry did not reveal evidence of 
significant publication bias (τ = -0.15, p = 0.510; Supplementary figure 3).  
 
 
Figure 4. Forest plot of studies investigating the effects of intranasal oxytocin on attentional bias 
towards disorder specific threat 
----------------------------------------------------------FIGURE 4--------------------------------------------------------------- 
Leppanen et al 2017 (a) = before smoothie challenge, Leppanen et al 2017 (b) = after smoothie 
challenge, AN = anorexia nervosa, BN = bulimia nervosa, ms = milliseconds, ITI = inter-trial interval. 
 
4.3.3 Fixation towards regions of interest 
The studies investigating the effects of a single dose of intranasal oxytocin on fixation towards ROIs 
in threatening images are presented in Figure 4. The meta-analysis showed that a single dose of 
oxytocin did not significantly influence fixation towards ROIs in threatening images (g = -0.08, 95% CI 
[-0.23, 0.08], Z = -0.96, p = 0.339).  
 
There was significant between-study heterogeneity (Q = 22.65, p = 0.031), which was explored 
further with meta-regressions.  The ROI used (QM = 1.53, p = 0.465), age (QM = 0.01, = 0.931), the 
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proportion of female participants in the study (QM = 0.28, p = 0.597), the study design (QM = 0.65, p 
= 0.419), the task used (QM = 1.53, p = 0.216), how fixation was measured (QM = 3.02, p = 0.388), 
the type of stimuli used (QM = 2.87, p = 0.238), the diagnosis (QM = 1.80, p = 0.179), and  the dose 
administered (QM = 0.25, p = 0.615) did not significantly moderate the heterogeneity.    
 
Begg’s rank correlation test based on the funnel plots did not reveal any significant publication bias 
(τ = -0.17, p = 0.435, Supplementary Figure 4). 
 
Figure 5. Forest plot of studies investigating the effects of intranasal oxytocin on fixation towards 
regions of interest in threating images 
----------------------------------------------------------FIGURE 5--------------------------------------------------------------- 
ROI = region of interest, BPD = borderline personality disorder. Lischke et al 2012a used predefined 
regions of interest based on pilot data. 
4.4 Effects of oxytocin on approach and avoidance responses to threat 
It was not possible to conduct a full meta-analysis of the studies investigating the effects of oxytocin 
on approach and avoidance responses due to the small number of studies and the variety of 
different outcome measures used. The significance of the findings from each study was then 
investigated by examining the 95% confidence intervals of the effect size estimates according to the 
guidelines stated in the Cochrane Handbook for Systematic Reviews (Higgins and Green, 2011).  
 
Two studies used a between subjects design to investigate the effects of a single dose of intranasal 
oxytocin on approach and avoidance reaction times (Preckel et al., 2014; Radke et al., 2017). The 
study by Preckel et al. (2014) examined only approach reaction times to social and non-social threat. 
The study found that intranasal oxytocin led to a small reduction in reaction times when 
approaching threatening social stimuli (ES = 0.34, 95% CI [-0.14, 0.83], total N = 67). There was a 
19 
 
negligible reduction in reaction times when approaching non-social threatening stimuli (ES = 0.07, 
95% CI [-0.41, 0.55], total N = 67). However, in both cases the 95% confidence intervals overlapped 
zero indicating that neither effect was statistically significant. Conversely, Radke et al. (2017) found 
that oxytocin led to a non-significant increase in approach reaction times towards social threat with 
a moderate effect size (ES = -0.51, 95% [-1.07, 0.04], total N = 52), and a significant increase in 
avoidance reaction times with a moderate effect size (ES = -0.56, 95% CI [-1.11, -0.002], total N = 52). 
These contradictory findings may be some way explained by the differences in sample size.  
 
Two studies by Radke et al. (2013) and Mitchell et al. (2016) used within subjects design to 
investigate approach/avoidance bias in healthy people and people with alcohol dependence disorder 
respectively. Radke et al. (2013) found a significant oxytocin-induced increase in approach bias 
towards threatening social stimuli with a moderate effect size among healthy individuals (ES = 0.52, 
95% CI [0.09, 0.95], N = 24). Similarly, Mitchell et al. (2016) found a negligible oxytocin-induced 
increase in approach bias towards threatening non-social stimuli in people with alcohol dependence 
disorder (ES = 0.16, 95% CI [-0.19, 0.51], N = 32), although this did not reach significance. Taken 
together these findings suggest that oxytocin may increase approach bias towards threatening 
stimuli, particularly threatening social stimuli. However, further research is needed to confirm this 
finding. 
 
Finally, the study by Theodoridou et al. (2013) used a between subjects design to investigate the 
effects of intranasal oxytocin on both approach and avoidance responses to social threat (total N = 
120). The authors did not report the relevant data to allow effect sizes to be calculated, but reported 
test statistics that showed no significant effect of intranasal oxytocin on approach or avoidance 
responses (Theodoridou et al., 2013).  
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Taken together these studies indicate that there is uncertainty about the effects of intranasal 
oxytocin on approach and avoidance responses to threatening stimuli. Indeed, the 95% confidence 
interval ranges in all studies were very wide (Higgins and Green 2011). Still, there was some 
indication that oxytocin may influence approach responses to threatening stimuli, particularly social 
threat. However, it is of interest that the two studies that showed significant effect size estimates 
also had smaller sample sizes (within subjects N = 24; between subjects N = 52) than the other 
studies reporting no significant effects of oxytocin (within subjects N = 32, between subjects N = 67 - 
120). Thus, further research with larger samples is needed. 
  
5 Discussion 
The aim of the present review was to examine the effects of a single dose of intranasal oxytocin on 
threat processing in healthy and clinical populations. The majority of the studies included only 
healthy individuals and no studies investigated the influence of intranasal oxytocin on the 
physiological startle response among clinical populations. The findings revealed that intranasal 
oxytocin significantly increased the startle response to threatening stimuli in healthy individuals with 
a small effect size. However, a single dose of intranasal oxytocin did not significantly influence 
attentional bias towards social threat or disorder specific threat, or fixation to regions of interest in 
threatening stimuli. The findings for effects of a single dose of oxytocin on approach and avoidance 
responses towards threat were inconsistent, calling for further research with large samples. 
Moreover, a single dose of intranasal oxytocin did not significantly influence attentional bias to 
social or disorder-specific threat among the clinical populations.  
 
In preclinical studies, oxytocin has been shown to facilitate extinction and generally inhibit anxiety- 
and fear-related responses and behaviours in rodents (Calcagnoli et al., 2015; Huber et al., 2005; 
Neumann and Slattery, 2016; Viviani et al., 2011). Conversely, the present review did not find 
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evidence of significant overall effects of intranasal oxytocin on attentional or behavioural approach 
or avoidance responses to threat in humans. Instead, we found that a single dose of intranasal 
oxytocin significantly increased startle response to threatening stimuli in healthy individuals. Based 
on the present findings, in healthy humans, oxytocin appears to primarily influence the salience of 
threatening stimuli, possibly indicating that oxytocin plays a role in arousal but not behavioural 
responding in humans. This interpretation is supported by findings from recent neuroimaging studies 
investigating neural responses to social threat in healthy humans. These studies have reported 
oxytocin-induced increases in neural activation in regions, including the amygdala, which are 
associated with processing of salience and arousal (Frijling et al., 2016; Gorka et al., 2015; Koch et 
al., 2016). This interpretation is further supported by findings from a previous meta-analysis that 
found that a single dose of intranasal oxytocin improved early detection of anger and late detection 
of fear in healthy humans (Shahrestani et al., 2013). Furthermore, a recent meta-analytic review by 
our group found that a single dose of oxytocin improved recognition of basic emotions, primarily 
fear and disgust, among healthy individuals (Leppanen et al., 2017). Thus, these findings suggest that 
rather than having global effects on threat processing, oxytocin may influence specific aspects of 
threat processing, such as arousal.  
 
 
Regarding clinical populations, the present review found that a single dose of intranasal oxytocin did 
not significantly influence attentional bias towards social threat among clinical populations. These 
findings are somewhat surprising considering the number of systematic reviews suggesting that 
oxytocin may be an effective new target for treatments in psychiatric disorders alleviating 
psychopathology in a number of disorders (Bakermans-Kranenburg and van Ijzendoorn, 2013; 
MacDonald and Feifel, 2013; MacDonald and MacDonald, 2010; Meyer-Lindenberg et al., 2011). One 
possible interpretation of the present findings is that although it may be effective in targeting certain 
symptoms, intranasal oxytocin may have little effect on threat processing among the clinical 
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populations. This interpretation is in line with findings from recent work investigating the 
effectiveness of intranasal oxytocin as a treatment enhancer in depression and BPD, which found 
that intranasal oxytocin did not improve anxiety or affiliative behaviour during therapy or clinical 
interview (Brune et al., 2015; MacDonald et al., 2013). Additionally, another study found that 
intranasal oxytocin did not improve self-reported anxiety among people with social anxiety disorder 
following exposure therapy (Guastella et al., 2009).  
 
It is of note, however, that the present review was only able to investigate the effects of a single 
dose of intranasal oxytocin attentional responses to threat among clinical populations due to lack of 
studies. Thus, it is possible that intranasal oxytocin does not have a significant effect on threat 
related attentional or behavioural responses, but may modulate other aspects of threat processing 
among clinical population. Indeed, a previous meta-analysis found that a single dose of oxytocin 
reduced the cortisol response to stressful stimuli among clinical populations (Cardoso et al., 2014). 
Similarly, a recent systematic review reported that intranasal oxytocin may be effective in combating 
anxiety and stress in disorder characterised by dysfunction of the central nervous system (Chapman 
et al., 2013). Furthermore, a recent experimental study found that a single dose of oxytocin 
increased heart rate response to trauma related stimuli while reducing self-reported trauma-related 
imagery among people with PTSD (Sack et al., 2017). These findings suggest that oxytocin may 
increase arousal while lowering stress and anxiety responses to threatening stimuli among clinical 
populations. However, further research with larger samples is still needed. 
 
Another possible interpretation of the present findings is that there is substantial heterogeneity 
within and between clinical groups that could dilute the true effects of intranasal oxytocin on social 
threat processing among clinical populations (Lamers et al., 2010; Melartin et al., 2002; Wessman et 
al., 2009). Indeed, in the present study there was significant between study heterogeneity in the 
meta-analysis investigating effects of oxytocin on attentional bias towards threat among clinical 
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populations. Findings from preclinical and human studies also suggest that the effects of oxytocin 
may be mediated by baseline levels of anxiety and other individual differences, such as attachment 
difficulties (Bartz et al., 2011; Bosch et al., 2005; Olff et al., 2013; Zik and Roberts, 2015). 
Environmental differences, such as the conditions under which participants are tested, have also 
been suggested to influence the effects of oxytocin (Bartz et al., 2011; Olff et al., 2013). This 
suggestion is in line with findings from our previous single dose study, which found that the effects 
of intranasal oxytocin on attentional bias towards food images in people with AN was dependent not 
only on whether the task was delivered before or after a smoothie challenge, but also on the inter-
trial interval used in the task (Leppanen et al., 2017). Although, further research could help gain 
better understanding of the effects of intranasal oxytocin on threat processing among clinical 
populations, these findings raise some questions about the therapeutic potential and effectiveness 
of intranasal oxytocin in the treatment of psychiatric disorders. 
 
5.1 Limitations and future directions 
The main limitation of this review is the small number of studies investigating the effects of 
intranasal oxytocin on different aspects of threat processing. Indeed, there were so few studies 
investigating the effects of a single dose of intranasal oxytocin on behavioural approach and 
avoidance responses to threatening stimuli, we were not able to conduct a full meta-analysis. 
Furthermore, only one of the studies reviewed here met our sample size requirement for adequate 
statistical power. These limitations were an issue when reviewing studies investigating the effects of 
a single dose of oxytocin on approach and avoidance responses. The only two that showed 
significant effects of oxytocin had smaller sample size than the other similar studies that did not 
show significant effects of oxytocin. It is possible that these findings were driven by the fact that 
smaller studies can sometimes overestimate effect sizes even when no true effect is present (Walum 
24 
 
et al., 2016; Zhang et al., 2013). These findings suggest that this is still a relatively unexplored field, 
and as further research with larger samples is needed.  
 
Additionally, there is relative paucity of research investigating the effects a single dose of intranasal 
oxytocin on threat processing among clinical populations. In the present review we were only able to 
investigate the effects of a single dose of oxytocin on attentional bias towards threat among clinical 
populations, but not the physiological startle response, approach and avoidance responses, or 
fixation response due to a lack of studies. Further research is needed to shed light on the effects of 
oxytocin on elevated threat sensitivity in psychiatric disorders.  
 
The dot-probe and spatial cueing tasks that were used to examine the effects of oxytocin on 
attention to social threat demonstrated that variation of task parameters, such as stimulus 
presentation time and inter-trial interval, had an impact on the effects of oxytocin. These factors 
added heterogeneity into the meta-analyses and influenced the interpretation of the findings. Short 
stimulus presentation duration is believed to tap into early attentional responses while longer 
stimulus duration is believed to examine late attention (Bantin et al., 2016). However, there are still 
some uncertainties regarding what should be used as the cut-off for early and late attention, with 
some eye tracking and electroencephalogram (EEG) studies reporting attentional shifts as early as 
200ms after stimulus onset (Bantin et al., 2016; Belyusar et al., 2013; Hedge and Leonards, 2013). 
Additionally, working memory and executive functioning studies have demonstrated that varying the 
inter-trial interval can impact performance, with shorter inter-trial intervals utilising more 
automated responding, while longer inter-trial intervals allow for more controlled responding 
(Cermak, 1970; Shipstead and Engle, 2013). Thus, to avoid these issues, future studies may benefit 
from utilising other methods to assess attentional bias, such as eye tracking or EEG, and working 
towards developing standardised measures.  
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Finally, there was significant between study heterogeneity in the meta-analysis investigating the 
effects of a single dose of oxytocin on attentional bias towards social threat and disorder-specific 
threat. Despite conducting meta-regressions to investigate moderating effects of age, dose, the type 
of task used, the type of stimuli used, and study design, we were not able to ascertain the source of 
the heterogeneity. Factors such as anxiety, attachment style, and alexithymia have been found to 
influence the effects of oxytocin on a number of different tasks (Bartz et al., 2011; Bosch et al., 2005; 
Olff et al., 2013; Zik and Roberts, 2015). However, since these variables were not explored or 
reported in the included studies we were unable to explore their moderator effects in the present 
review. Thus, further work investigating potential moderators of the effects of oxytocin on 
attentional bias towards threatening stimuli would be of interest.  
 
6 Conclusions 
The aim of the present review was to examine the effects of a single dose of intranasal oxytocin on 
threat processing in healthy and clinical populations. The findings revealed that oxytocin significantly 
increased the physiological startle response to threat in healthy people with a small effect size. 
Oxytocin did not have significant effects on attentional bias towards social or disorder-specific threat 
or on fixation towards threatening stimuli among healthy or clinical populations. There was also no 
convincing evidence that oxytocin significantly influences threat related behavioural approach or 
avoidance responses. These findings suggest that oxytocin may primarily influence the salience of 
threatening stimuli possibly indicating that oxytocin plays a role in emotional, but not behavioural 
processing in humans. Large scale research investigating the effects of oxytocin on physiological 
startle response among clinical populations would be of interest.  
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9 Figure legends 
Figure 1. Literature search flow diagram 
 
Figure 2. Forest plot of studies investigating the effects of intranasal oxytocin on physiological 
response to threat. Grillon et al. 2013(a) = female participants, Grillon et al. 2013(b) = male 
participants, Angry faces (f) = angry female faces, Angry faces (m) = angry male faces, EMG = 
electromyography. 
 
Figure 3. Forest plot of studies investigating the effects of intranasal oxytocin on attentional bias 
towards social threat. Ellenbogen et al. 2012 (a) = congruent trials, Ellenbogen et al. 2012 (b) = 
incongruent trials, AN = anorexia nervosa; BN = bulimia nervosa; BPD = borderline personality 
disorder, ms = milliseconds.  
 
Figure 4. Forest plot of studies investigating the effects of intranasal oxytocin on attentional bias 
towards disorder specific threat. Leppanen et al 2017 (a) = before smoothie challenge, Leppanen et 
al 2017 (b) = after smoothie challenge, AN = anorexia nervosa, BN = bulimia nervosa, ms = 
milliseconds, ITI = inter-trial interval. 
 
Figure 5. Forest plot of studies investigating the effects of intranasal oxytocin on fixation towards 
regions of interest in threating images. Lischke et al. 2012a used predefined regions of interest 
based on pilot data. ROI = region of interest, BPD = borderline personality disorder. 
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Eye 
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Predicta
ble 
shock 
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shock 
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No 
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-
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2013 
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days 
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40 
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dilation 
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respons
e 
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0.44 
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1, 
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Lischke et al. 
2012a      
Withi
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subje
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24 
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45 
min 
Healthy  
N = 14 
% 
female = 
23.79 
(2.32) 
Fixation 
during 
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Fixation 
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n 
Predefin
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negative 
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0.00 
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0.52
, 
No 
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week
s 
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) 
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] 
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0.37 
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, 
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] 
Lischke et al. 
2012b      
Betw
een 
subje
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24 
IU 
45 
min 
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Oxytocin 
= 20 
Placebo 
= 24 
% 
female = 
0 
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26.09 
(3.41) 
Fixation 
during 
emotion 
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on  
Relative 
fixation 
duratio
n 
Eyes of 
angry 
faces 
0.38 
[-
0.22
, 
0.97
] 
No 
Mouth 
of angry 
faces 
-
0.45 
[-
1.04
, 
0.15
] 
Preckel et al. 
2014 
Betw
een 
subje
cts 
24 
IU 
45 
min 
Healthy 
Oxytocin 
= 33 
Placebo 
= 34 
% 
female = 
100 
Oxytoc
in = 
23.61 
(2.71) 
Placeb
o = 
23.74 
(2.47) 
Approach 
/ 
avoidanc
e task 
Approa
ch 
reaction 
time 
(ms) 
Negative 
social 
stimuli 
0.34 
[-
0.14
, 
0.83
] 
No 
Negative 
non-
social 
stimuli 
-
0.07 
[-
0.55
, 
0.41
] 
Prehn et al. 
2013 
Betw
een 
subje
cts 
24 
IU 
45 
min 
Healthy  
Oxytocin 
= 23 
Placebo 
= 24 
% 
female =  
Oxytoc
in = 
25.78 
(3.37) 
Placeb
o = 
26.38 
(3.49) 
Startle 
response 
during 
emotion 
recogniti
on task 
Pupil 
dilation 
startle 
respons
e 
Angry 
male 
faces 
0.54 
[-
0.04
, 
1.12
] 
No 
Angry 
female 
faces 
0.26 
[-
0.31
, 
0.84
] 
Radke et al. 
2013 
Withi
n 
subje
cts 
(sessi
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14 
days 
apart
24 
IU 
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min 
Healthy  
N = 24 
% 
female = 
0 
21.46 
(1.93) 
Approach 
/ 
avoidanc
e task 
Approa
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ce bias 
Angry 
faces 
0.52  
[0.0
9, 
0.95
] 
No 
45 
 
) 
Radke et al. 
2017 
Betw
een 
subje
cts 
24 
IU 
45 
min 
Healthy  
Oxytocin 
= 24 
Placebo 
= 28 
% 
female = 
0 
Total: 
22.4 
(3) 
Approach 
/ 
avoidanc
e task 
Approa
ch 
reaction 
time 
(ms) 
Angry 
faces 
-
0.51 
[-
1.07
, 
0.04
] 
No 
Avoidan
ce 
reaction 
time 
(ms) 
-
0.56 
[-
1.11
, -
0.00
2] 
Striepens et al. 
2012 
Betw
een 
subje
cts 
24 
IU 
45 
min 
Healthy 
Oxytocin 
= 36 
Placebo 
= 33 
% 
female = 
0 
Oxytoc
in = 
24.28 
(2.86) 
Placeb
o = 
25.03 
(2.56) 
Startle 
response 
to 
negative 
images 
Eye 
blink 
magnitu
de 
startle 
respons
e 
Negative 
IAPS 
images 
0.70 
[0.2
1, 
1.18
] 
 
Theodoridou et 
al. 2013 
Betw
een 
subje
cts 
24 
IU 
35 
min 
Healthy 
Oxytocin 
= 60 
Placebo 
= 60 
% 
female = 
50  
Total: 
22.4 
(range 
= 18.1-
43.8)  
Approach 
/ 
avoidanc
e task 
Approa
ch 
reaction 
time 
(ms) 
Angry 
faces 
NR* No 
Disguste
d faces 
Avoidan
ce 
reaction 
time 
(ms) 
Angry 
faces 
Disguste
d faces 
Clinical 
Bertsch et al. 
2013    
Betw
een 
subje
cts 
24 
IU 
45 
min 
BPD 
Oxytocin 
= 19 
Placebo 
= 19 
% 
female = 
100 
Oxytoc
in = 
23.2 
(5.3) 
Placeb
o = 
24.9 
(5.5) 
Fixation 
during 
emotion 
recogniti
on task 
Fixation 
changes 
Eyes of 
angry 
faces 
-
0.70 
[-
1.33
, -
0.06
] 
No 
Mouth 
of angry 
faces 
-
0.21 
[-
0.85
, 
0.44
] 
Brune et al. 
2013  
Withi
n 
subje
cts 
(sessi
ons 
5-7 
days 
24 
IU 
45 
min 
BPD 
N = 13 
% 
female = 
61.54 
 Dot-
probe 
(200ms/5
00ms 
stimulus 
presentat
ion with 
500ms 
Attentio
nal bias 
Angry 
faces 
1.30 
[0.5
6, 
2.04
] 
No 
46 
 
apart
) 
ITI) 
Clark-Elford et 
al. 2015    
Withi
n 
subje
cts 
(sessi
ons 7 
days 
apart
) 
24 
IU 
45 
min 
Highly 
anxious 
people 
N = 16 
% 
female = 
0 
27.13 
(9.25) 
Dot-
probe 
(500ms 
stimulus 
presentat
ion with 
500-
1250ms 
ITI) 
Attentio
nal bias 
Angry 
faces 
-
0.42 
[-
0.93
, 
0.09
] 
No 
Domes et al. 
2016 
Betw
een 
subje
cts 
24 
IU 
60 
min 
Depressi
on 
Oxytocin 
= 22 
Placebo 
= 21 
% 
female =  
58.14  
Oxytoc
in = 
46.7 
(11.1) 
Placeb
o = 
47.2 
(9.0) 
Dot-
probe 
(100ms 
stimulus 
presentat
ion with 
750–
1500ms 
ITI) 
Attentio
nal bias 
Angry 
faces 
0.50 
[-
0.10
, 
1.10
] 
No 
Dot-
probe 
(600ms 
stimulus 
presentat
ion with 
750–
1500ms 
ITI) 
0.14 
[-
0.46
, 
0.73
] 
Dot-
probe 
(1200ms 
stimulus 
presentat
ion with 
750–
1500ms 
ITI) 
-
0.33 
[-
0.93
, 
0.27
] 
Kim et al. 
2014a         
Withi
n 
subje
cts 
(sessi
ons 
4-7 
days 
apart
) 
40 
IU 
45 
min 
AN 
N = 31 
% 
female = 
100 
23.10 
(9.35) 
Dot-
probe 
(500ms 
stimulus 
presentat
ion with 
750ms 
ITI) 
Attentio
nal bias 
Angry 
faces 
0.50 
[0.1
3, 
0.87
] 
No 
Disguste
d faces 
-
0.28 
[-
0.64
, 
0.08
] 
Kim et al. 
2014c           
Withi
n 
subje
cts 
(sessi
ons 
40 
IU 
45 
min 
AN 
N = 31 
% 
female = 
100 
23.10 
(9.35) 
Dot-
probe 
(1000ms 
stimulus 
presentat
ion with 
Attentio
nal bias 
Food-
related 
stimuli 
-
0.40 
[-
0.77
, -
0.03
No 
47 
 
4-7 
days 
apart
) 
750ms 
ITI) 
] 
Body 
shape-
related 
stimuli 
-
0.38 
[-
0.75
, -
0.02
] 
Body 
weight-
related 
stimuli 
0.02 
[-
0.33
, 
0.37
] 
Kim et al. In 
prep. 
Withi
n 
subje
cts 
(sessi
ons  
40 
IU 
45 
min 
BN 
N = 31 
% 
female = 
100 
23.87(
3.99) 
Dot-
probe 
(500ms 
stimulus 
presentat
ion with 
750ms 
ITI) 
Attentio
nal bias 
Angry 
faces 
-
0.22 
[-
0.57
, 
0.14
] 
No 
Disguste
d faces 
0.09 
[-
0.26
, 
0.44
] 
Food-
related 
stimuli 
0.12 
[-
0.23
, 
0.47
] 
Body 
shape-
related 
stimuli 
0.36 
[-
0.00
02, 
0.73
] 
Body 
weight-
related 
stimuli 
-
0.00
5 [-
0.36
, 
0.35
] 
Dot-
probe 
(1000ms 
stimulus 
presentat
ion with 
750ms 
ITI) 
Angry 
faces 
-
0.47 
[-
0.84
, -
0.10
] 
 
Disguste
d faces 
0.04 
[-
48 
 
0.31
, 
0.39
] 
Food-
related 
stimuli 
0.09 
[-
0.26
, 
0.44
] 
Body 
shape-
related 
stimuli 
0.08 
[-
0.27
, 
0.43
] 
Body 
weight-
related 
stimuli 
0.28 
[-
0.08
, 
0.64
] 
Leppanen et al. 
2017 
Withi
n 
subje
cts 
(sessi
ons 
1-5 
days 
apart
) 
40 
IU 
55 
min 
(befor
e 
smoot
hie 
challe
nge) 
AN 
N = 30 
% 
female = 
100 
 
26.2 
(6.82) 
Dot-
probe 
(500ms 
stimulus 
presentat
ion with 
500ms 
ITI) 
Attentio
nal bias 
Food-
related 
stimuli 
0.26 
[-
0.11
, 
0.62
] 
No 
Dot-
probe 
(500ms 
stimulus 
presentat
ion with 
1250ms 
ITI) 
-
0.22 
[-
0.58
, 
0.14
] 
80 
min 
(after 
smoot
hie 
challe
nge) 
Dot-
probe 
(500ms 
stimulus 
presentat
ion with 
500ms 
ITI) 
-
0.47 
[-
0.85
, -
0.10
] 
Dot-
probe 
(500ms 
stimulus 
presentat
ion with 
1250ms 
ITI) 
0.02 
[-
0.34
, 
0.38
] 
Mitchell et al. 
2016 
Withi
n 
40 
IU 
30 
min 
Alcohol 
depend
28.9 
(7.15) 
Approach 
/ 
Approa
ch / 
Negative 
IAPS 
0.16 
[-
No 
49 
 
subje
cts 
(sessi
ons 7 
days 
apart
) 
ence 
Disorder 
N = 32 
% 
female =  
40.63  
avoidanc
e task 
avoidan
ce bias 
images 0.19
, 
0.51
] 
ES = effect size estimate (either standardised mean difference or standardised mean change); IU = 
international unit; SD = standard deviation; EMG = electromyography; min = minutes; ms = 
milliseconds; ES = effect size; SCT = spatial cueing task; ITI = inter-trial interval; ROI = region of 
interest; IAPS = International Affective Picture System; BPD = borderline personality disorder; AN = 
anorexia nervosa; BN = bulimia nervosa; NR = not reported. The Power column indicates whether or 
not the studies met our sample size requirement to have 80% power to detect at least a moderate 
difference between oxytocin and placebo.  
*Relevant data was not reported in the paper 
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Highlights 
- The review explores the effects of intranasal oxytocin on threat processing  
- Intranasal oxytocin increased startle response to threat in healthy people 
- No significant effects on attentional or approach responses were observed 
 
